Welcome to our dedicated page for IPG PHOTONICS SEC filings (Ticker: IPGP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IPG Photonics Corporation filings document an operating company whose common stock trades on the Nasdaq Global Select Market under IPGP. Its Form 8-K reports furnish quarterly operating results and financial condition updates, including revenue by application, margins, EBITDA, earnings measures, capital expenditures and business factors such as demand, tariffs, product costs and inventory management.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting, along with 8-K disclosures for governance and compensation arrangements such as the amended executive severance plan. Other event reports document intellectual-property matters involving IPG Laser GmbH & Co. KG, adjustable mode beam lasers, Unified Patent Court decisions and the global patent-litigation settlement with TRUMPF.
Amendment No. 7 to Schedule 13D for IPG Photonics Corporation updates beneficial ownership information for several major holders of the company’s common stock. Reported percentages are calculated using 42,443,616 shares of common stock outstanding as of May 4, 2026.
The Valentin Gapontsev Trust I reports beneficial ownership of 6,670,283 shares, or 15.7% of the class. Angelo P. Lopresti reports 8,095,986 shares (19.1%). IQ EQ Trust Company, U.S., LLC reports 8,328,919 shares (19.6%). Eugene A. Shcherbakov reports 14,577,710 shares, representing 34.3% of IPG Photonics’ common stock.
IPG Photonics Corporation has a significant shareholder disclosure from IP Fibre Devices (UK) Ltd, which filed an amended Schedule 13G. The reporting person, organized under the laws of the United Kingdom, reports beneficial ownership of 6,463,302 shares of IPG Photonics common stock, par value $0.0001 per share.
This holding represents 15.2% of the outstanding common stock. IP Fibre Devices (UK) Ltd reports sole voting power and sole dispositive power over all 6,463,302 shares, with no shared voting or dispositive power. The filing is signed by Dr. Eugene A. Scherbakov as Managing Director of the reporting person.
IPG Photonics Corp ten percent owner Valentin Gapontsev Trust I reported selling a total of 56,316 shares of common stock on July 21, 2026 in four sale transactions. The weighted average prices were $100.08, $101.20, $102.04 and $103.00 per share, each covering multiple trades within stated price ranges. The sales were effected pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026.
IPG Photonics Corporation agreed a Put Option Agreement with Lumibird S.A. for the proposed acquisition of 100% of Lumibird Medical for a cash purchase price of €300 million, on a cash-free, debt-free basis, plus up to €50 million earnout tied to 2026–2027 performance. IPG Photonics plans to fund the deal with cash on hand. After completion of the required French works council consultation and the seller’s exercise of the put, IPG Photonics is irrevocably committed to sign a share purchase agreement, with closing targeted in the fourth quarter of 2026, subject to customary conditions and authorization under the French foreign direct investment regime.
The agreements include exclusivity for IPG Photonics, warranty and indemnity insurance covering many seller warranties, capped seller liability for business warranties, and three-year non-compete and non-solicitation provisions on the seller. Lumibird Medical generated 2025 revenue of €112.2 million and EBITDA of €24.1 million, and IPG Photonics describes the business as high-margin and expects the acquisition to be accretive to gross margin, EBITDA and adjusted EPS while adding approximately $1 billion to the Advanced Solutions addressable market. A supplemental investor presentation indicates the €300 million price equals 15.9x 2025 adjusted EBITDA of €18.9 million and that the combined medical businesses would have about $204 million of 2025 sales.
IPG Photonics Corp large shareholder IP Fibre Devices Ltd, a ten percent owner, reported open-market sales of a total of 65,700 shares of common stock on June 29, 2026.
The shares were sold in multiple transactions at prices ranging from $99.55 to $106.87 per share, with several tranches reported at weighted-average prices between about $100.19 and $106.40. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. Following the transactions, IP Fibre Devices Ltd directly holds 6,463,302 shares of IPG Photonics common stock.
IPG Photonics senior vice president, secretary and general counsel Angelo P. Lopresti sold 1,000 shares of common stock in an open-market transaction at a weighted average price of $110.33 per share. After the sale, he directly holds 59,841 shares.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026, indicating it was scheduled in advance rather than timed discretionarily. Individual sale prices ranged from $110.15 to $110.47 per share.
IPG Photonics director and 10% owner Eugene A. Scherbakov sold 1,524 shares of common stock in open-market transactions. The sales occurred on June 29, 2026 at prices just above $100 per share, including trades at $100.43, $101.24, $102.92, $104.63 and $106.66.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026, indicating they were scheduled in advance. After these transactions, Scherbakov directly owns 49,734 shares of IPG Photonics common stock.
IPGP affiliate submitted a Form 144 to sell 3,000 shares of Common Stock. The filing lists a broker as Stifel Nicolaus & Company Inc. and shows an aggregate amount of $331,000.00 and a Nasdaq listing date of 06/29/2026. The excerpt also lists several Restricted Stock Units grants with issuance dates and share counts: 1,458, 253, 607, and 682.
IPGP filed a Form 144 notice reporting proposed sales of Common Stock tied to previously granted restricted stock units. The filing lists multiple RSU grant vintages with specified share counts and identifies Nasdaq as the market referenced.